

1 **Humoral responses against BQ.1.1 elicited after breakthrough infection and SARS-**  
2 **CoV-2 mRNA vaccination**

3 Alexandra Tauzin<sup>1,2</sup>, Mehdi Benlarbi<sup>1,2</sup>, Halima Medjahed<sup>1</sup>, Yves Grégoire<sup>3</sup>, Josée  
4 Perreault<sup>3</sup>, Gabrielle Gendron-Lepage<sup>1</sup>, Laurie Gokool<sup>1</sup>, Chantal Morisseau<sup>1</sup>, Pascale  
5 Arlotto<sup>1</sup>, Cécile Tremblay<sup>1</sup>, Daniel E. Kaufmann<sup>1,4,5</sup>, Valérie-Martel-Laferrrière<sup>1,2</sup>, Inès  
6 Levade<sup>6</sup>, Marceline Côté<sup>7</sup>, Gaston de Serres<sup>8</sup>, Renée Bazin<sup>3</sup>, and Andrés Finzi<sup>1,2,#</sup>

7

8 <sup>1</sup>Centre de Recherche du CHUM, Montreal, QC, Canada

9 <sup>2</sup>Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC, Canada

10 <sup>3</sup>Héma-Québec, Affaires Médicales et Innovation, Quebec, QC, Canada

11 <sup>4</sup>Département de Médecine, Université de Montréal, Montreal, QC, Canada

12 <sup>5</sup>Division of Infectious Diseases, Department of Medicine, University Hospital of Lausanne and University of  
13 Lausanne, Lausanne, Switzerland

14 <sup>6</sup>Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne de-  
15 Bellevue, QC, Canada.

16 <sup>7</sup>Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity, and  
17 Inflammation, University of Ottawa, Ottawa, ON, Canada

18 <sup>8</sup>Institut National de Santé Publique du Québec, Quebec, QC, Canada

19

20 # Correspondance: Andrés Finzi, [andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)

21 **Abstract**

22

23 The Omicron BQ.1.1 variant is now the major SARS-CoV-2 circulating strain in many  
24 countries. Because of the many mutations present in its Spike glycoprotein, this variant is  
25 resistant to humoral responses elicited by monovalent mRNA vaccines. With the goal to  
26 improve immune responses against Omicron subvariants, bivalent mRNA vaccines have  
27 recently been approved in several countries. In this study, we measure the capacity of plasma  
28 from vaccinated individuals, before and after a fourth dose of mono- or bivalent mRNA  
29 vaccine, to recognize and neutralize the ancestral (D614G) and the BQ.1.1 Spikes. Before  
30 and after the fourth dose, we observe a significantly better recognition and neutralization of  
31 the ancestral Spike. We also observe that fourth-dose vaccinated individuals who have been  
32 recently infected recognize and neutralize better the BQ.1.1 Spike, independently of the  
33 mRNA vaccine used, than donors who have never been infected or have an older infection.  
34 Our study supports that hybrid immunity, generated by vaccination and a recent infection,  
35 induces higher humoral responses than vaccination alone, independently of the mRNA  
36 vaccine used.

37

38 **Keywords:** COVID-19, SARS-CoV-2, mRNA bivalent vaccine, Hybrid immunity, Humoral  
39 responses, BQ.1.1

## 40 **Introduction**

41 The Omicron BQ.1.1 variant is a sublineage of the BA.5 variant that spreads very rapidly  
42 and is now the major circulating lineage in several countries [1,2]. Recent studies have shown  
43 that original SARS-CoV-2 mRNA vaccines, based on the ancestral Wuhan strain Spike (S),  
44 lead to poor humoral responses against several Omicron subvariants, including the BQ.1.1  
45 variant [3–5]. With the goal to improve immune responses against these subvariants,  
46 Moderna and Pfizer bivalent vaccines have recently been approved by health authorities in  
47 many countries [6–8]. These updated versions of the vaccines are composed of mRNA coding  
48 for the expression of both the ancestral and an Omicron subvariant S [9,10]. However, the  
49 continued evolution of SARS-CoV-2 has resulted in the emergence of multiple Omicron sub-  
50 lineages showing signs of convergent evolution by the acquisition of the same immune  
51 escape mutation in the RBD region of the Spike protein. Notably, all five recent convergent  
52 mutations are present in BQ. 1.1: R346T, K444T, L452R, N460K, or F486V [3]. Because of  
53 these newly acquired mutations, the benefits of bivalent compared to monovalent vaccines  
54 against this lineage remain to be established.

55 It is well accepted now that hybrid immunity leads to better immune responses and  
56 protection from severe outcomes than vaccination alone [11–17]. Because the original  
57 mRNA vaccines poorly prevent viral transmission, an important part of the vaccinated  
58 population have been recently infected by Omicron subvariants, leading to improved immune  
59 responses in these individuals compared to SARS-CoV-2 naïve individuals who have just  
60 been vaccinated.

61 In this study, we evaluated the capacity of plasma antibodies to recognize and neutralize  
62 the original D614G and the Omicron BQ.1.1 subvariant S four weeks (W4-Va3) and four  
63 months (M4-Va3) after the third dose and four weeks after the fourth dose (W4-Va4) of  
64 mRNA vaccines (Figure 1A). These participants mainly received as their first three doses of  
65 vaccine the Pfizer monovalent vaccine, and as the fourth dose either the Pfizer or Moderna  
66 monovalent or Pfizer (BA.4/5) or Moderna (BA.1) bivalent vaccines. We also measured the  
67 anti-nucleocapsid (N) level to determine if the donors had recent breakthrough infection

68 (BTI), i.e., they have been infected between their third and fourth doses of vaccine by a  
69 Omicron sublineage. Basic demographic characteristics of the cohort are summarized in  
70 Table 1.

71

## 72 **Materials and Methods**

### 73 **Ethics statement**

74 The study was conducted in accordance with the Declaration of Helsinki in terms of  
75 informed consent and approval by an appropriate institutional board. The protocol was  
76 approved by the Ethics Committee of CHUM (19.381, approved on February 28, 2022) and  
77 Héma-Québec (2022-016, approved on October 7, 2022).

### 78 **Human subjects**

79 The study was conducted in 63 individuals (25 males and 38 females; age range: 24-84  
80 years). 20 of these individuals had recent breakthrough infection with an Omicron sublineage  
81 (9 males and 11 females; age range: 24-67 years), i.e. as determined by the increase in anti-  
82 N levels between W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 using a recently  
83 described analytical approach [18] (Figure S1). For the other donors (16 males and 27  
84 females; age range: 31-84 years), we did not observe a significant increase of the anti-N  
85 levels, although some of them have a history of infection. No other specific criteria such as  
86 number of patients (sample size), sex, clinical or demographic were used for inclusion.

### 87 **Plasma samples and antibodies**

88 Plasma samples were either recovered from whole blood or directly obtained from the  
89 PlasCov biobank [19], heat-inactivated for 1 hour at 56°C and stored at -80°C until use in  
90 subsequent experiments. Pre-pandemic plasma samples were used as negative controls in  
91 cytometry assays (data not shown). The conformationally independent S2-specific  
92 monoclonal antibody CV3-25 was used as a positive control and to normalize Spike  
93 expression in flow cytometry assays, as described [4,20–23]. Alexa Fluor-647-conjugated  
94 goat anti-human antibodies (Abs) able to detect all Ig isotypes (anti-human IgM+IgG+IgA;  
95 Jackson ImmunoResearch Laboratories, Cat # 109-605-064) were used as secondary Abs to  
96 detect plasma binding in flow cytometry experiments.

### 97 **Plasmids**

98 The plasmids encoding the SARS-CoV-2 D614G and BQ.1.1 Spike variants were  
99 previously described [4]. The pNL4.3 R-E-Luc plasmid was obtained from the NIH AIDS  
100 Reagent Program (Cat# 3418). The pIRES2-EGFP expressing plasmid was purchased from  
101 Clontech (Cat# 6029-1).

## 102 **Cell lines**

103 293T human embryonic kidney cells (obtained from ATCC, Cat# CRL-3216) were  
104 maintained at 37°C under 5% CO<sub>2</sub> in Dulbecco's modified Eagle's medium (DMEM)  
105 (Wisent) containing 5% fetal bovine serum (FBS) (VWR) and 100 µg/ml of penicillin-  
106 streptomycin (Wisent). 293T-ACE2 cell line was previously reported [24].

## 107 **Enzyme-linked immunosorbent assay (ELISA)**

108 All samples were tested for anti-N total immunoglobulin levels using an in-house anti-  
109 N ELISA. The assay protocol is similar to the anti-SARS-CoV-2 RBD ELISA previously  
110 developed by our group [25], except that recombinant N (Centre National en Électrochimie  
111 et en Technologies Environnementales Inc., Shawinigan, Canada) was used (0.25 µg/ml) in  
112 lieu of the RBD antigen (2.5 µg/ml).

## 113 **Cell surface staining and flow cytometry analysis**

114 293T were transfected with full-length SARS-CoV-2 Spikes and a green fluorescent  
115 protein (GFP) expressor (pIRES2-eGFP) using the calcium-phosphate method. Two days  
116 post-transfection, Spike-expressing 293T cells were stained with the CV3-25 Ab (5 µg/mL)  
117 as control or plasma (1:250 dilution) for 45 min at 37°C. AlexaFluor-647-conjugated goat  
118 anti-human IgM+IgG+IgA (1/800 dilution) were used as secondary Abs. The percentage of  
119 Spike-expressing cells (GFP + cells) was determined by gating the living cell population  
120 based on viability dye staining (Aqua Vivid, Invitrogen). Samples were acquired on a  
121 LSRFortessa cytometer (BD Biosciences), and data analysis was performed using FlowJo  
122 v10.7.1 (Tree Star). The conformationally-independent anti-S2 antibody CV3-25, effective  
123 against all Spike variants, was used to normalize Spike expression, as reported [4,20,22,23].  
124 The Median Fluorescence intensities (MFI) obtained with plasma were normalized to the  
125 MFI obtained with CV3-25 and presented as percentage of CV3-25 binding.

## 126 **Virus neutralization assay**

127 293T cells were transfected with the lentiviral vector pNL4.3 R-E- Luc and a plasmid  
128 encoding the D614G or the BQ.1.1 S glycoprotein at a ratio of 10:1 to produce SARS-CoV-

129 2 pseudoviruses. Two days post-transfection, cell supernatants were harvested and stored at  
130  $-80^{\circ}\text{C}$  until use. For the neutralization assay, 293T-ACE2 target cells were seeded at a  
131 density of  $1 \times 10^4$  cells/well in 96-well luminometer-compatible tissue culture plates  
132 (PerkinElmer) 24h before infection. Pseudoviral particles were incubated with several plasma  
133 dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at  $37^{\circ}\text{C}$  and were then added to the  
134 target cells followed by incubation for 48h at  $37^{\circ}\text{C}$ . Cells were lysed by the addition of 30  $\mu\text{L}$   
135 of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 TriStar  
136 luminometer (Berthold Technologies) was used to measure the luciferase activity of each  
137 well after the addition of 100  $\mu\text{L}$  of luciferin buffer (15mM  $\text{MgSO}_4$ , 15mM  $\text{KH}_2\text{PO}_4$  [pH  
138 7.8], 1mM ATP, and 1mM dithiothreitol) and 50  $\mu\text{L}$  of 1mM d-luciferin potassium salt  
139 (Prolume). The neutralization half-maximal inhibitory dilution ( $\text{ID}_{50}$ ) represents the plasma  
140 dilution to inhibit 50% of the infection of 293T-ACE2 cells by pseudoviruses.

#### 141 **Statistical analysis**

142 Symbols represent biologically independent samples from individuals. Statistics were  
143 analyzed using GraphPad Prism version 8.0.1 (GraphPad, San Diego, CA). Each dataset was  
144 tested for statistical normality and this information was used to apply the appropriate  
145 (parametric or nonparametric) statistical test. p values  $< 0.05$  were considered significant;  
146 significance values are indicated as \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ , ns, non-  
147 significant.

148

#### 149 **Results**

150 We first monitored the capacity of plasma to recognize the D614G and BQ.1.1 Spikes  
151 after the third and fourth doses of mRNA vaccine by flow cytometry (Figure 1B-D). For the  
152 D614G S, no significant differences were observed four weeks and four months after the  
153 third dose of vaccine between individuals with or without recent BTI. In contrast, four weeks  
154 after the fourth dose of mRNA vaccine, individuals with recent BTI recognized better the  
155 D614G S than donors with no recent BTI regardless of the vaccine type received (Figure 1B).  
156 For the BQ.1.1 S, at the M4-Va3 timepoint donors with recent BTI better recognized the S  
157 than individuals with no recent infection, and this difference in recognition was more

158 significant four weeks after the fourth dose (Figure 1C). The level of BQ.1.1 S recognition  
159 was significantly lower compared to D614G S in donors without recent BTI (Figure 1D), in  
160 agreement with recent reports [4,5]. In donors who had recently been infected, there was a  
161 significant but smaller difference in the level of recognition between the two Spikes  
162 compared to the other group.

163

164 We also measured the neutralizing activity of plasma against the D614G and BQ.1.1 S  
165 (Figure 1E-G). We observed pattern similar to that measured for Spike recognition. No  
166 significant differences were observed between the two groups at W4-Va3 and M4-Va3  
167 timepoints (Figure 1E-F). In contrast, four weeks after the fourth dose, donors with recent  
168 BTI had a significantly higher level of neutralizing activity against D614G and BQ.1.1 S. All  
169 donors with recent BTI who received a fourth dose developed neutralizing antibodies against  
170 BQ.1.1 S, while some donors who just received four doses of vaccine were still not able to  
171 neutralize this Spike. As observed for S recognition (Figure 1D), BQ.1.1 Spike was  
172 significantly less neutralized than D614G S, even after four doses of mRNA vaccine (Figure  
173 1G). However, the difference in neutralization between the two S was smaller in the group  
174 with recent BTI.

175

176 The Moderna BA.1 bivalent vaccine (blue points) tended to induce better recognition and  
177 neutralization than the other vaccine platforms including the Pfizer BA.4/5 bivalent vaccine  
178 with lesser decrease of recognition and neutralization of BQ.1.1 S (Figure 1B-G, Figure S2).  
179 These differences did not reach statistical significance; whether this is due to the relatively  
180 low number of samples tested remains to be determined.

181

182

## 183 **Discussion**

184 Since its emergence in late 2021, the Omicron variant continues to evolve into new  
185 subvariants that are increasingly resistant to monoclonal antibodies and vaccination [5,26–  
186 30]. To address vaccine resistance, bivalent mRNA vaccines, expressing both the original

187 Spike and one of the parental lineages of Omicron (BA.1 or BA.4/5) Spike, have been  
188 developed and are now being administered in several jurisdictions worldwide. However,  
189 although the bivalent mRNA vaccine has been shown to increase the level of protection  
190 against BA.5 variant in mice [31], evidence of its superior effectiveness in the human  
191 population remains to be demonstrated, especially against sub-lineages with newly acquired  
192 immune escape mutations. Recent studies showed that both monovalent and bivalent  
193 vaccines induced low humoral responses against BQ.1.1, but recent breakthrough infection  
194 before vaccination strongly improved these responses [32]. The results presented herein  
195 support these observations.

196 As previously reported in numerous studies, including ours, hybrid immunity led to  
197 better humoral responses against the BQ.1.1 and other recent variants than just vaccination  
198 [4,5,32]. Also, we observed that after 4 doses of mRNA vaccine and no recent BTI, some  
199 donors did not have neutralizing activity against pseudoviral particles bearing the BQ.1.1  
200 Spike. Whether these changes of recognition and neutralization translate into greater risk of  
201 severe disease is currently unknown. In contrast, BTI likely increased the breadth of  
202 neutralizing antibodies since all donors had detectable levels of neutralization against  
203 BQ.1.1.

204

205 These results indicate that further efforts have to be devoted to improve vaccines against  
206 new SARS-CoV-2 variants of concern. Whether immune responses comparable to those  
207 observed with breakthrough infections could be obtained with new vaccine formulations  
208 remains to be determined.

209

210 **Author Contributions:** A.T., R.B. and A.F. conceived the study. A.T., M.B., H.M., J.P.,  
211 G.G-L., R.B. and A.F. performed, analyzed, and interpreted the experiments. A.T. performed  
212 statistical analysis. H.M., G.G-L., M.C., and A.F. contributed unique reagents. L.G., P.A.,  
213 C.M., C.T., D.E.K., Y.G. and V.M.-L. collected and provided clinical samples. R.B., G.D.S.,  
214 and I.L. provided scientific input related to VOCs and vaccine efficacy. A.T. and A.F. wrote  
215 the manuscript with inputs from others. Every author has read, edited and approved the final  
216 manuscript.



217 **Funding:** This work was supported by le Ministère de l'Économie et de l'Innovation du  
218 Québec, Programme de soutien aux organismes de recherche et d'innovation to A.F. and by  
219 the Fondation du CHUM. This work was also supported by a CIHR foundation grant  
220 #352417, by a CIHR operating Pandemic and Health Emergencies Research grant #177958,  
221 by an Exceptional Fund COVID-19 from the Canada Foundation for Innovation (CFI)  
222 #41027 to A.F. The PlasCov biobank was supported by funding from the COVID-19  
223 Immunity Task Force (CITF) which is supported by the Public Health Agency of Canada  
224 (PHAC). Work on variants presented was also supported by the Sentinelle COVID Quebec  
225 network led by the LSPQ in collaboration with Fonds de Recherche du Québec Santé (FRQS)  
226 to A.F. A.F. is the recipient of Canada Research Chair on Retroviral Entry no. RCHS0235  
227 950-232424. C.T. is the Pfizer/Université de Montréal Chair on HIV translational research.  
228 V.M.-L is supported by a FRQS Junior 2 salary award. A.T. was supported by MITACS  
229 Accélération postdoctoral fellowship. M.B. was the recipient of a CIHR master's scholarship  
230 award. The funders had no role in study design, data collection and analysis, decision to  
231 publish, or preparation of the manuscript. We declare no competing interests.

232

233 **Institutional Review Board Statement:** The study was conducted in accordance with the  
234 Declaration of Helsinki in terms of informed consent and approval by an appropriate  
235 institutional board. The protocol was approved by the Ethics Committee of CHUM (19.381,  
236 approved on February 28, 2022) and Héma-Québec (2022-016, approved on October 7,  
237 2022).

238

239 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in  
240 the study.

241

242 **Data Availability Statement:** Further information, data reported in this paper, and requests  
243 for resources and reagents should be directed to and will be fulfilled by the lead contact,  
244 Andrés Finzi ([andres.finzi@umontreal.ca](mailto:andres.finzi@umontreal.ca)) upon request.

245

246 **Acknowledgments:** The authors are grateful to the donors who participated in this study.

247 The authors thank the CRCHUM BSL3 and Flow Cytometry Platforms for technical

248 assistance.

249

250 **Conflicts of Interest:** The authors declare no conflict of interest.

## 251 **References**

- 252 1. Données sur les variants du SRAS-CoV-2 au Québec Available online:  
253 <https://www.inspq.qc.ca/covid-19/donnees/variants> (accessed on 6 December 2022).
- 254 2. CDC COVID Data Tracker Weekly Review Available online:  
255 <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html> (accessed on  
256 6 December 2022).
- 257 3. Qu, P.; Evans, J.P.; Faraone, J.; Zheng, Y.-M.; Carlin, C.; Anghelina, M.; Stevens, P.;  
258 Fernandez, S.; Jones, D.; Lozanski, G.; et al. Enhanced Neutralization Resistance of SARS-  
259 CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2. *Cell Host &*  
260 *Microbe* **2022**, doi:10.1016/j.chom.2022.11.012.
- 261 4. Tauzin, A.; Nicolas, A.; Ding, S.; Benlarbi, M.; Medjahed, H.; Chatterjee, D.; Dionne,  
262 K.; Gong, S.Y.; Gendron-Lepage, G.; Bo, Y.; et al. SARS-CoV-2 Omicron Subvariants Spike  
263 Recognition and Neutralization Elicited after the Third Dose of mRNA Vaccine 2022,  
264 2022.08.03.22278386.
- 265 5. Kurhade, C.; Zou, J.; Xia, H.; Liu, M.; Chang, H.C.; Ren, P.; Xie, X.; Shi, P.-Y. Low  
266 Neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1, and XBB.1 by Parental mRNA  
267 Vaccine or a BA.5-Bivalent Booster. *Nat Med* **2022**, 1–1, doi:10.1038/s41591-022-02162-x.
- 268 6. FDA Coronavirus (COVID-19) Update: FDA Authorizes Moderna, Pfizer-BioNTech  
269 Bivalent COVID-19 Vaccines for Use as a Booster Dose, [https://www.fda.gov/news-  
270 events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-  
271 pfizer-biontech-bivalent-covid-19-vaccines-use](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use) Available online:  
272 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-  
273 authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use) (accessed on 6  
274 December 2022).
- 275 7. EMA First Adapted COVID-19 Booster Vaccines Recommended for Approval in the  
276 EU, [https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-  
277 recommended-approval-eu](https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu) Available online: [https://www.ema.europa.eu/en/news/first-  
278 adapted-covid-19-booster-vaccines-recommended-approval-eu](https://www.ema.europa.eu/en/news/first-adapted-covid-19-booster-vaccines-recommended-approval-eu) (accessed on 6 December  
279 2022).
- 280 8. Health Canada Health Canada Authorizes COVID-19 Vaccine Booster Targeting the  
281 Omicron BA.4/BA.5 Subvariants, [https://www.canada.ca/en/health-  
282 canada/news/2022/10/health-canada-authorizes-covid-19-vaccine-booster-targeting-  
283 the-omicron-ba4ba5-subvariants.html](https://www.canada.ca/en/health-canada/news/2022/10/health-canada-authorizes-covid-19-vaccine-booster-targeting-the-omicron-ba4ba5-subvariants.html) Available online: [https://www.canada.ca/en/health-  
284 canada/news/2022/10/health-canada-authorizes-covid-19-vaccine-booster-targeting-the-  
285 omicron-ba4ba5-subvariants.html](https://www.canada.ca/en/health-canada/news/2022/10/health-canada-authorizes-covid-19-vaccine-booster-targeting-the-omicron-ba4ba5-subvariants.html) (accessed on 6 December 2022).
- 286 9. Pfizer and BioNTech Complete Submission to European Medicines Agency for Omicron  
287 BA.4/BA.5 Adapted Bivalent Vaccine | Pfizer Available online:  
288 [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-  
289 complete-submission-european-medicines](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-complete-submission-european-medicines) (accessed on 6 December 2022).
- 290 10. Canada | SPIKEVAX™ Information Available online:  
291 <https://www.modernacovid19global.com/ca/> (accessed on 6 December 2022).

- 292 11. Ntziora, F.; Kostaki, E.G.; Karapanou, A.; Mylona, M.; Tseti, I.; Sipsas, N.V.;  
293 Paraskevis, D.; Sfrikakis, P.P. Protection of Vaccination versus Hybrid Immunity against  
294 Infection with COVID-19 Omicron Variants among Health-Care Workers. *Vaccine* **2022**, *40*,  
295 7195–7200, doi:10.1016/j.vaccine.2022.09.042.
- 296 12. Altarawneh, H.N.; Chemaitelly, H.; Ayoub, H.H.; Tang, P.; Hasan, M.R.; Yassine, H.M.;  
297 Al-Khatib, H.A.; Smatti, M.K.; Coyle, P.; Al-Kanaani, Z.; et al. Effects of Previous Infection  
298 and Vaccination on Symptomatic Omicron Infections. *N Engl J Med* **2022**, *387*, 21–34,  
299 doi:10.1056/NEJMoa2203965.
- 300 13. Carazo, S.; Skowronski, D.M.; Brisson, M.; Barkati, S.; Sauvageau, C.; Brousseau, N.;  
301 Gilca, R.; Fafard, J.; Talbot, D.; Ouakki, M.; et al. Protection against Omicron (B.1.1.529)  
302 BA.2 Reinfection Conferred by Primary Omicron BA.1 or Pre-Omicron SARS-CoV-2  
303 Infection among Health-Care Workers with and without mRNA Vaccination: A Test-  
304 Negative Case-Control Study. *The Lancet Infectious Diseases* **2022**, *0*, doi:10.1016/S1473-  
305 3099(22)00578-3.
- 306 14. Tauzin, A.; Nayrac, M.; Benlarbi, M.; Gong, S.Y.; Gasser, R.; Beaudoin-Bussièrès, G.;  
307 Brassard, N.; Laumaea, A.; Vézina, D.; Prévost, J.; et al. A Single Dose of the SARS-CoV-  
308 2 Vaccine BNT162b2 Elicits Fc-Mediated Antibody Effector Functions and T Cell  
309 Responses. *Cell Host & Microbe* **2021**, *0*, doi:10.1016/j.chom.2021.06.001.
- 310 15. Tauzin, A.; Gong, S.Y.; Beaudoin-Bussièrès, G.; Vézina, D.; Gasser, R.; Nault, L.;  
311 Marchitto, L.; Benlarbi, M.; Chatterjee, D.; Nayrac, M.; et al. Strong Humoral Immune  
312 Responses against SARS-CoV-2 Spike after BNT162b2 mRNA Vaccination with a 16-Week  
313 Interval between Doses. *Cell Host & Microbe* **2022**, *30*, 97-109.e5,  
314 doi:10.1016/j.chom.2021.12.004.
- 315 16. Stamatatos, L.; Czartoski, J.; Wan, Y.-H.; Homad, L.J.; Rubin, V.; Glantz, H.; Neradilek,  
316 M.; Seydoux, E.; Jennewein, M.F.; MacCamy, A.J.; et al. mRNA Vaccination Boosts Cross-  
317 Variant Neutralizing Antibodies Elicited by SARS-CoV-2 Infection. *Science* **2021**,  
318 eabg9175, doi:10.1126/science.abg9175.
- 319 17. Tauzin, A.; Gong, S.Y.; Chatterjee, D.; Ding, S.; Painter, M.M.; Goel, R.R.; Beaudoin-  
320 Bussièrès, G.; Marchitto, L.; Boutin, M.; Laumaea, A.; et al. A Boost with SARS-CoV-2  
321 BNT162b2 mRNA Vaccine Elicits Strong Humoral Responses Independently of the Interval  
322 between the First Two Doses. *Cell Reports* **2022**, *41*, doi:10.1016/j.celrep.2022.111554.
- 323 18. Bazin, R.; Rochette, S.; Perreault, J.; Fournier, M.-J.; Grégoire, Y.; Boivin, A.; Lewin,  
324 A.; Germain, M.; Renaud, C. Development and Use of a Method Based on the Anti-N  
325 Reactivity of Longitudinal Samples to Better Estimate SARS-CoV-2 Seroprevalence in a  
326 Vaccinated Population 2022, 2022.08.15.22278798.
- 327 19. Germain, M.; Lewin, A.; Bazin, R.; Dieudé, M.; Perreault, J.; Boivin, A.; Grégoire, Y.;  
328 Renaud, C. Cohort Profile: A Québec-Based Plasma Donor Biobank to Study COVID-19  
329 Immunity (PlasCoV) 2022, 2022.11.09.22282156.
- 330 20. Prévost, J.; Richard, J.; Gasser, R.; Ding, S.; Fage, C.; Anand, S.P.; Adam, D.; Vergara,  
331 N.G.; Tauzin, A.; Benlarbi, M.; et al. Impact of Temperature on the Affinity of SARS-CoV-  
332 2 Spike Glycoprotein for Host ACE2. *J Biol Chem* **2021**, 101151,  
333 doi:10.1016/j.jbc.2021.101151.

- 334 21. Jennewein, M.F.; MacCamy, A.J.; Akins, N.R.; Feng, J.; Homad, L.J.; Hurlburt, N.K.;  
335 Seydoux, E.; Wan, Y.-H.; Stuart, A.B.; Edara, V.V.; et al. Isolation and Characterization of  
336 Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. *Cell Rep* **2021**, *36*,  
337 109353, doi:10.1016/j.celrep.2021.109353.
- 338 22. Gong, S.Y.; Chatterjee, D.; Richard, J.; Prévost, J.; Tauzin, A.; Gasser, R.; Bo, Y.;  
339 Vézina, D.; Goyette, G.; Gendron-Lepage, G.; et al. Contribution of Single Mutations to  
340 Selected SARS-CoV-2 Emerging Variants Spike Antigenicity. *Virology* **2021**, *563*, 134–145,  
341 doi:10.1016/j.virol.2021.09.001.
- 342 23. Chatterjee, D.; Tauzin, A.; Marchitto, L.; Gong, S.Y.; Boutin, M.; Bourassa, C.;  
343 Beaudoin-Bussièrès, G.; Bo, Y.; Ding, S.; Laumaea, A.; et al. SARS-CoV-2 Omicron Spike  
344 Recognition by Plasma from Individuals Receiving BNT162b2 mRNA Vaccination with a  
345 16-Week Interval between Doses. *Cell Rep* **2022**, 110429, doi:10.1016/j.celrep.2022.110429.
- 346 24. Prévost, J.; Gasser, R.; Beaudoin-Bussièrès, G.; Richard, J.; Duerr, R.; Laumaea, A.;  
347 Anand, S.P.; Goyette, G.; Benlarbi, M.; Ding, S.; et al. Cross-Sectional Evaluation of  
348 Humoral Responses against SARS-CoV-2 Spike. *Cell Rep Med* **2020**, *1*, 100126,  
349 doi:10.1016/j.xcrm.2020.100126.
- 350 25. Perreault, J.; Tremblay, T.; Fournier, M.-J.; Drouin, M.; Beaudoin-Bussièrès, G.;  
351 Prévost, J.; Lewin, A.; Bégin, P.; Finzi, A.; Bazin, R. Waning of SARS-CoV-2 RBD  
352 Antibodies in Longitudinal Convalescent Plasma Samples within 4 Months after Symptom  
353 Onset. *Blood* **2020**, *136*, 2588–2591, doi:10.1182/blood.2020008367.
- 354 26. Qu, P.; Faraone, J.; Evans, J.P.; Zou, X.; Zheng, Y.-M.; Carlin, C.; Bednash, J.S.;  
355 Lozanski, G.; Mallampalli, R.K.; Saif, L.J.; et al. Neutralization of the SARS-CoV-2  
356 Omicron BA.4/5 and BA.2.12.1 Subvariants. *New England Journal of Medicine* **2022**, *386*,  
357 2526–2528, doi:10.1056/NEJMc2206725.
- 358 27. Tuekprakhon, A.; Nutalai, R.; Dijokaite-Guraliuc, A.; Zhou, D.; Ginn, H.M.; Selvaraj,  
359 M.; Liu, C.; Mentzer, A.J.; Supasa, P.; Duyvesteyn, H.M.E.; et al. Antibody Escape of SARS-  
360 CoV-2 Omicron BA.4 and BA.5 from Vaccine and BA.1 Serum. *Cell* **2022**, *185*, 2422-  
361 2433.e13, doi:10.1016/j.cell.2022.06.005.
- 362 28. Wang, Q.; Guo, Y.; Iketani, S.; Nair, M.S.; Li, Z.; Mohri, H.; Wang, M.; Yu, J.; Bowen,  
363 A.D.; Chang, J.Y.; et al. Antibody Evasion by SARS-CoV-2 Omicron Subvariants  
364 BA.2.12.1, BA.4, & BA.5. *Nature* **2022**, 1–3, doi:10.1038/s41586-022-05053-w.
- 365 29. Sheward, D.J.; Kim, C.; Fischbach, J.; Sato, K.; Muschiol, S.; Ehling, R.A.; Björkström,  
366 N.K.; Hedestam, G.B.K.; Reddy, S.T.; Albert, J.; et al. Omicron Sublineage BA.2.75.2  
367 Exhibits Extensive Escape from Neutralising Antibodies. *The Lancet Infectious Diseases*  
368 **2022**, *0*, doi:10.1016/S1473-3099(22)00663-6.
- 369 30. Arora, P.; Kempf, A.; Nehlmeier, I.; Schulz, S.R.; Jäck, H.-M.; Pöhlmann, S.; Hoffmann,  
370 M. Omicron Sublineage BQ.1.1 Resistance to Monoclonal Antibodies. *The Lancet Infectious*  
371 *Diseases* **2022**, *0*, doi:10.1016/S1473-3099(22)00733-2.
- 372 31. Scheaffer, S.M.; Lee, D.; Whitener, B.; Ying, B.; Wu, K.; Liang, C.-Y.; Jani, H.; Martin,  
373 P.; Amato, N.J.; Avena, L.E.; et al. Bivalent SARS-CoV-2 mRNA Vaccines Increase  
374 Breadth of Neutralization and Protect against the BA.5 Omicron Variant in Mice. *Nat Med*  
375 **2022**, 1–11, doi:10.1038/s41591-022-02092-8.


376 32. Hoffmann, M.; Behrens, G.M.N.; Arora, P.; Kempf, A.; Nehlmeier, I.; Cossmann, A.;  
377 Manthey, L.; Dopfer-Jablonka, A.; Pöhlmann, S. Effect of Hybrid Immunity and Bivalent  
378 Booster Vaccination on Omicron Sublineage Neutralisation. *The Lancet Infectious Diseases*  
379 **2022**, *0*, doi:10.1016/S1473-3099(22)00792-7.  
380  
381

382 **Table 1. Characteristics of the SARS-CoV-2 vaccinated cohort**

		<b>Entire cohort</b>	<b>No recent BTI</b>	<b>Recent BTI</b>
<b>Number</b>		63	43	20
<b>Age**</b>		59 (24-84)	63 (31-84)	54 (24-67)
<b>Sex</b>	<b>Female (n)</b>	38	27	11
	<b>Male (n)</b>	25	16	9
<b>Days between the third and fourth doses****</b>		186 (101-313)	155 (101-271)	268 (134-313)
<b>Fourth dose</b>	<b>Pfizer monovalent</b>	28	22	6
	<b>Moderna monovalent</b>	21	18	3
	<b>Pfizer BA.4/5</b>	4	1	3
	<b>Moderna BA.1</b>	10	2	8
<b>Days between the third and W4-Va3</b>		26 (17-45)	25 (17-45)	28 (18-41)
<b>Days between the third and M4-Va3</b>		120 (90-194)	120 (90-194)	122 (92-150)
<b>Days between the fourth and W4-Va4</b>		28 (18-96)	28 (18-96)	25 (20-42)

383 Values displayed are medians, with ranges in parentheses. Continuous variables between  
384 individuals with no recent and recent BTI were compared by using Mann-Whitney tests.  $p <$   
385 0.05 was considered statistically significant for all analyses. Statistical differences between  
386 the two groups were found for the age of the donors and the interval between the third and  
387 fourth doses of vaccine. (\*\*  $P < 0.01$ ; \*\*\*\*  $P < 0.0001$ ).






388

389 **Figure 1. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the third**  
 390 **and fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent**  
 391 **breakthrough infection. (A) SARS-CoV-2 vaccine cohort design. The yellow box identifies**  
 392 **the three timepoints under study shown in panels B, C, E and F and the red box the period**  
 393 **presented in panels D and G. (B-D) 293T cells were transfected with the full-length D614G**  
 394 **or BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and**  
 395 **analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb**  
 396 **binding. (E-G) Neutralization activity was measured by incubating pseudoviruses bearing**  
 397 **SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting**  
 398 **293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were**  
 399 **determined using a normalized non-linear regression using GraphPad Prism software.**  
 400 **Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent**



401 (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple  
402 and blue points respectively. Limits of detection are plotted. Error bars indicate means  $\pm$   
403 SEM. (\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*\*  $P < 0.0001$ ; ns, non-significant).  
404



405

406 **Figure S1. Anti-N level measured after the third and fourth doses of SARS-CoV-2**

407 **vaccine.** Anti-N level was measured in plasma from vaccinated donors by ELISA. Donors

408 are considered to have a recent BTI when a significant increase of anti-N Abs level between


409 W4-Va3 and M4-Va3 or between M4-Va3 and W4-Va4 is observed, according to a recently

410 described analytical approach based on the ratio of anti-N absorbance. Individuals with no

411 recent BTI and recent BTI are represented by gray and red dots respectively. (\* P < 0.05;

412 \*\*\*\* P < 0.0001; ns, non-significant).

413



414

415 **Figure S2. Recognition and neutralization of the D614G and BQ.1.1 Spikes after the**  
 416 **fourth doses of SARS-CoV-2 vaccine in individuals with or without a recent**  
 417 **breakthrough infection.** (A) 293T cells were transfected with the full-length D614G or  
 418 BQ.1.1 S, stained with the CV3-25 mAb or with plasma from vaccinated individuals and  
 419 analyzed by flow cytometry. The values represent the MFI normalized by CV3-25 mAb  
 420 binding. (B) Neutralization activity was measured by incubating pseudoviruses bearing  
 421 SARS-CoV-2 S glycoproteins, with serial dilutions of plasma for 1 h at 37°C before infecting  
 422 293T-ACE2 cells. Neutralization half maximal inhibitory serum dilution (ID<sub>50</sub>) values were  
 423 determined using a normalized non-linear regression using GraphPad Prism software.  
 424 Individuals vaccinated with Pfizer monovalent, Moderna monovalent, Pfizer bivalent  
 425 (BA.4/5) or Moderna bivalent (BA.1) fourth dose are represented by orange, green, purple  
 426 and blue points respectively. Limits of detection are plotted. Error bars indicate means ±  
 427 SEM.